期刊文献+

超说明书用药司法判例中的药学分析 被引量:15

Pharmaceutical Analysis of Judicial Precedents Involving Off-label Drug Use
原文传递
导出
摘要 目的通过对13例涉及超说明书用药司法判例中的药学部分进行分析,探讨目前我国对超说明书用药的司法解释,以期为我国超说明书用药的制度建立及临床应用提供借鉴与参考。方法通过对中国裁判文书网、北大法宝、聚法案例、无讼案例4个法律数据库进行检索,对其中涉及超说明书用药的13个司法判例进行汇总,分析判例中不同判决结果与超说明书用药的关系。结果 13例判例中,具有合理性或不宜当然推定医方存在过错2例,欠合理但与结果无关2例,存在过错且与患者结局存在因果关系9例。判决存在过错且与患者结局存在因果关系的案例中,循证依据不足4例,知情同意特殊风险告知不足3例,用药后监护不足1例,特异质反应1例,符合同成分药物其他版本说明书,但由于未符合所用药物说明书用法1例。结论涉及超说明书用药的司法判例中,超说明书用药制度不完善、知情同意告知不清及无循证依据是判决不合理判例中存在的主要问题。建立更为完善的超说明书用药制度、规范超说明书用药知情同意交代及临床应用前进行反复循证分析论证是确保超说明书用药安全的重要手段。 OBJECTIVE To analyze 13 judicial precedents involving off-label drug use and explore the legal interpretation on off-label drug use in China in order to provide experience for establishment of off-label drug use and clinical application. METHODS Based on the law databases (China Judgements Online, Chinalawinfo, Jufaanli, Itslaw) , 13 cases were searched and screened involving legal off-label drug use. The relationship was investigated and discussed between different results and characteristics of the 13 cases. RESULTS In 13 eases, there are 2 cases probably reasonable for off-label use, 2 cases unreasonable but not correlated with patients' outcomes, 9 unreasonable and with a causal relationship with patients' outcomes. In the 9 unreasonable cases, there are 4 cases without sufficient evidence, 3 cases without informed consent, 1 case lack of monitoring after off-label use, 1 case with idiosyncratic reaction, and 1 ease not consistent with the label of the drug used. CONCLUSION Major deficiencies of off-label drug use in China are without sufficient evidence, lack of informed consent and with uncompleted system on off-label drug use. Establishing more completed and detailed system, investigating enough clinical evidence, better informed consent and monitoring after off-label use are important measurements to ensure safety on off-label drug use.
作者 杜博冉 冯欣 史湘君 阴赪宏 唐彦 邹羽真 杨阳 李漠 DU Bo-ran;FENG Xin;SHI Xiang-jun;YIN Cheng-hong;TANG Yan;ZOU Yu-zhen;YANG Yang;LI Mo(Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100026,China;School of Pharmaceutical Science,Tsinghua University,Beijing 100084,China;Peking Union Medical College Hospital,Beijing 100032,China;Peking Dacheng Law Firm,Beijing 100020,China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2018年第21期1876-1880,共5页 Chinese Pharmaceutical Journal
基金 北京市科委十病十药研发项目资助(Z151100003815016)
关键词 超说明书用药 司法判例 药学分析 原因分析 措施分析 off-label drug use judicial precedent pharmaceutical analysis causation analysis measurement analysis
  • 相关文献

参考文献8

二级参考文献128

  • 1张波,李大魁,杨晓.“药品说明书之外的用法”的若干问题及对策[J].继续医学教育,2006,20(28):86-88. 被引量:16
  • 2广东省药学会.药品未注册用法专家共识.2010年3月18日.
  • 3邵蓉,蒋正华,黄泰康.医疗机构涉药人员执业风险防范与规避[J].中国药房,2007,18(28):2163-2164. 被引量:25
  • 4American Society of Hospital Pharmacists. ASHP statement on the use of medications for unlabeled uses. Am Hospital Pharm, 1992, 49(8): 2006-2008.
  • 5Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liver- pool Women's Hospital. The International ournal Of Pharmacy Practice, 2010, 18(4): 226-229.
  • 6Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BM, 2000, 320(7227): 79-82.
  • 7Hames A. Unlicensed and off-label drug use in elderly people. Age And Ageing, 2001, 30(6): 530-531.
  • 8Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypi- cal antipsychotic drugs in patients with Alzheimer's Disease. N Engl Med, 2006, 355(15): 1525-1538.
  • 9Huntzinger A. FDA warns against off-label use of antipsychotic drugs. Am Faro Physician, 2005, 71(61): 2205.
  • 10Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med, 2006, 166(9): 1021-1026.

共引文献438

同被引文献121

引证文献15

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部